Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk warns of 2026 sales decline, shares fall
Novo Nordisk (NYSE:NVO) shares fell almost 13% on Tuesday as the Danish drugmaker forecast lower sales and profit growth for 2026, citing reduced prices in the United States and loss of exclusivity for its blockbuster GLP-1 drugs Wegovy and Ozempic in several markets. For 2026, Novo Nordisk expects adjusted sales and operating profit to decline between 5% and 13% at constant exchange rates, reversing last year's 10% sales growth.
Wegovy Maker Novo Nordisk Forecasts Sales Decline in 2026
The Danish drugmaker said adjusted sales should decline between 5% and 13% at constant exchange rates in 2026, a reversal from last year, when sales grew 10%.
Novo Nordisk shares tumble 11% after company forecasts sales declines this year
Novo Nordisk said late Tuesday it sees sales and profit growth declining this year, expecting a U.S. sales hit. Novo's American depositary shares fell 11% on the news.
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study
Novo Nordisk reports that CagriSema beats semaglutide at HbA1c reduction and weight loss in a 68-week phase III diabetes study, with no weight-loss plateau.
Citi flags bigger tests ahead after Novo Nordisk diabetes trial success
Bank says latest CagriSema results meet expectations, with investor focus shifting to head-to-head data against Eli Lilly's tirzepatide. Novo Nordisk (NYSE:NVO) has reported positive headline results from a late-stage trial of its next-generation diabetes drug CagriSema, but analysts at Citi said the data were largely expected and that more consequential readouts lie ahead.
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
NVO faces slowing Wegovy and Ozempic sales momentum, pricing pressures and fierce competition ahead of Q4 earnings.
Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
Novo Nordisk A/S has first-mover advantage in obesity pills and aggressive U.S. marketing, supported by a robust cash position, strengthen its competitive stance in the thriving GLP-1 market. Consensus revenue growth forecasts appear overly pessimistic given NVO's historical double-digit growth and Q4 seasonal strength. Despite positives, technical setup, high valuation (PEG 3.3 vs. 1.8 sector median), and potential profit-taking temper enthusiasm make NVO a Hold.
Novo Nordisk's China President Zhou to step down in March
Danish pharmaceutical company Novo Nordisk said on Friday that Senior Vice President and head of its business in China Christine Zhou will leave the company at the end of March.
Novo Nordisk: Investors May Be In For An Earnings Surprise
Novo Nordisk could be poised for a temporary negative sentiment swing as Q4 earnings may include highly conservative 2026 guidance despite strong oral Wegovy prescription momentum. Recent news - such as oral Wegovy's rapid uptake, Lilly's FDA delays, UK approval, and an Amazon partnership have all fueled a 20% rally, but upside appears limited pre-earnings. Management is likely to under promise on 2026 guidance to set up a runway for consistent beats and positive revisions as oral Wegovy's impact materializes, in my view.
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
Novo Nordisk (NVO) reached $62.89 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?
NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.
Novo Nordisk: The Q4 Setup Favors Another Beat (Earnings Preview)
Novo Nordisk A/S's restructuring costs are front-loaded in Q3, with DKK 1 billion in savings accruing to Q4 earnings, setting up a potential beat on low expectations. The FDA-approved Wegovy oral pill launched in January 2026 with 18,000+ prescriptions in its debut week, expanding the addressable market to approximately 85 million Americans. Catalent fill-finish site integration is expected to double U.S. supply chain capacity by mid-2026, supporting margin expansion and reducing manufacturing bottlenecks going forward.
